


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

PRESENTATION AND ASSESSMENT

TREATMENT



FiO₂ = fraction of inspired oxygen
MAP = mean arterial pressure
PaCO₂ = partial pressure of carbon dioxide
ROSC = return of spontaneous circulation
SBP = systolic blood pressure

¹ Evaluation and recommendations to be documented in progress notes

² Neurological status should not be used to determine need for immediate angiography


³ Optimal blood pressure should be determined based on optimal organ and brain perfusion for the individual patient

⁴ Refer to [GCC home page](#) (for internal use only)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

FURTHER ASSESSMENT AND TREATMENT

DISPOSITION



EEG = electroencephalogram
GFR = glomerular filtration rate

¹ Neurological status should not be used to determine need for immediate angiography
² Evaluation and recommendations to be documented in progress notes
³ Reduce loading dose to 20 mg/kg IV if patient is already on levetiracetam (Keppra®) or GFR < 50 mL/minute/1.73 m²

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

APPENDIX A: Prognostic Considerations

Note: Not every patient with return of spontaneous circulation (ROSC) will require every test

- Patients who remain comatose in the absence of confounders after ROSC should be evaluated for neurological prognosis, at the earliest, 72 hours after ROSC
- Patients with underlying terminal disease, brain herniation, or other non-survivable situations may be considered for withdrawal of care within 72 hours of ROSC
- Determining neurologic prognosis should be based on a multi-modal approach with a primary focus on clinical assessment. Diagnostic testing which may aid in neurological prognosis include but are not limited to those listed below.
 - Clinical assessment
 - Bilaterally absent pupillary light reflex at 72 hours or more after ROSC
 - Absence of corneal and oculoccephalic reflexes at 72 hours or more after ROSC
 - Neurophysiology testing
 - Somatosensory evoked potentials (SSEP) waves in combination with other indices¹
 - Malignant EEG patterns² in combination with other indices
 - Persistent and refractory electrographic seizures
 - Imaging
 - Repeat CT head without contrast for gray white matter distinction³
 - MRI brain without contrast to include diffusion-weighted (DWI), apparent diffusion coefficient (ADC), and fluid-attenuated inversion recovery (FLAIR) sequences
 - Imaging for brain death diagnosis as indicated (see [Determination of Death by Neurological Criteria algorithm](#))
 - Nuclear medicine brain scan with vascular flow
 - Transcranial doppler ultrasonography (TCD)
 - Biomarkers
 - Neuron-specific enolase (NSE) at 24 and 72 hours of ROSC^{4,5,6}

¹ A significant peripheral neuropathy, spinal cord metastasis, and/or brain metastasis may preclude accurate recordings

² Examples of malignant EEG patterns include non reactive EEG in the presence of very low voltage recording, significant burst suppression, generalized periodic discharges, alpha theta coma and stimulus triggered discharges

³ Gray matter to white matter ratio may be considered when possible

⁴ A NSE value of 40-60 micrograms/L or an upward trend has higher specificity for outcome prediction

⁵ NSE could be elevated in certain cancers such as small cell lung cancer and other carcinoid tumors, hemodialysis, brain conditions (limbic encephalitis)

⁶ Neurofilament assay could be considered if NSE is not elevated in the appropriate clinical context (use Misc Reference Lab order)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Berg, K. M., Soar, J., Anderson, L. W., Bottiger, B. W., Cacciola, S., Callaway, C. W., . . . Nolan, J. P. (2020). Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Circulation*, 142(Suppl 1), S92-S139. <https://doi.org/10.1161/CIR.0000000000000893>
- Endisch, C., Westhall, E., Kenda, M., Streitberger, K. J., Kirkegaard, H., Stenzel, W., . . . Leithner, C. (2020). Hypoxic-ischemic encephalopathy evaluated by brain autopsy and neuroprognostication after cardiac arrest. *JAMA Neurology*, 77(11), 1430-1439. <https://doi.org/10.1001/jamaneurol.2020.2340>
- Genton, P., & Gelisse, P. (2001). Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. *Neurology*, 57(6), 1144-1145. <https://doi.org/10.1212/WNL.57.6.1144-b>
- Hawkes, M. A., & Rabinstein, A. A. (2019). Neurological prognostication after cardiac arrest in the era of target temperature management. *Current Neurology and Neuroscience Reports*, 19(10), 10-17. <https://doi.org/10.1007/s11910-019-0922-2>
- Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., . . . Silbergleit, R. (2019). Randomized trial of three anticonvulsant medications for status epilepticus. *The New England Journal of Medicine*, 381(22), 2103-2113. <https://doi.org/10.1056/NEJMoa1905795>
- MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy
Advance Care Planning (ACP) Conversation Workflow (ATT1925)
- Muhlhofer, W., & Szaflarski, J. P. (2018). Prognostic value of EEG in patients after cardiac arrest - An updated review. *Current Neurology and Neuroscience Reports*, 18(16), 16-30. <https://doi.org/10.1007/s11910-018-0826-6>
- Venot, M., Weiss, N., Espinoza, S., Imbert, A., Tadie, J.-M., Fagon, J.-Y., . . . Diehl, J.-L. (2011). Improvement of early diagnosed post-anoxic myoclonus with levetiracetam. *Intensive Care Medicine*, 37, 177-179. <https://doi.org/10.1007/s00134-010-2055-6>
- Wihersaari, L., Reinikainen, M., Furlan, R., Mandelli, A., Vaahersalo, J., Kurola, J., . . . Skrifvars, M. B. (2022). Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. *Resuscitation*. 174, 1-8. <https://doi.org/10.1016/j.resuscitation.2022.02.024>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Cardiopulmonary Resuscitation experts at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Core Development Team Leads

John Crommett, MD (Critical Care Medicine)
Karen Plexman, MSN, RN (Code Blue Operations)

Workgroup Members

Patricia Brock, MD (Emergency Medicine)
Matthew Debnam, MD (Neuroradiology)
Wendy Garcia, BS♦
Petra Grami, DNP, RN (Nursing Administration)
Nandita Guha-Thakurta, MD (Neuroradiology)
Kaveh Karimzad, MD (Cardiology)
Murray, Jeanneé Campbell, MPAS, PA-C (Critical Care Medicine)
Joseph Nates, MD (Critical Care Medicine)
Egbert Pravinkumar, MD, FRCP (Critical Care Medicine)
Mary Lou Warren, DNP, APRN, CNS-CC♦

♦Clinical Effectiveness Development Team